A new study found that compound heatwaves significantly increase cardiac mortality and are more impactful than traditional binary definitions of heatwaves.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
Dr. Christopher Kramer began a one-year term as head of the American College of Cardiology, addressing workforce issues, health equity and AI-driven solutions to improve cardiovascular care. With over 35 years of membership and leadership roles, Kramer brings experience in cardiovascular magnetic resonance imaging.
Dr. David Winchester will lead the American College of Cardiology's Board of Governors, guiding chapters representing all 50 states and promoting heart health improvement in communities. His term aims to address practice challenges through advocacy and chapter support.
The BHF PROTECT-TAVI trial found no reduction in stroke rate for patients undergoing TAVR with an embolic protection device. Despite its large sample size, the study showed that cerebral embolic protection devices do not improve outcomes for TAVR patients.
A large randomized controlled trial found no significant difference in health status between patients with restricted and unrestricted fluid intake. Despite this, patients on fluid restriction reported more thirst and had lower overall health scores at baseline compared to those with liberal fluid intake.
A minimally invasive procedure using a clip to repair the tricuspid valve significantly reduced symptom severity and decreased recurrent hospitalization for heart failure. The study found a 28% reduction in hospitalizations at two years, with improved safety and effectiveness compared to medical therapy alone.
A new study has found that clopidogrel outperforms aspirin monotherapy in reducing heart attack rates without increasing bleeding risk in high-risk patients following percutaneous coronary intervention (PCI). Researchers observed a significant reduction in ischemic endpoints, primarily driven by a decrease in heart attacks.
A new study found that survival rates for athletes suffering sudden cardiac arrest vary significantly by race, with 57% of Black athletes and 54% of other race athletes dying between 2014-2023. Improved emergency preparedness likely played a role in increased survival rates.
A study found that intravenous iron supplementation resulted in a 20% lower risk of cardiovascular death or first heart failure hospitalization, as well as improved symptoms and quality of life. The benefits were most pronounced in the first year after treatment, suggesting a meaningful association between iron dosage and outcomes.
Patients who received nurse-led follow-up care had a 30% lower rate of cardiovascular death, non-fatal heart attacks, or strokes at five years compared to those receiving standard care. This was achieved through improved lifestyle habits and medication adherence.
Early IABP use did not improve 60-day survival or transition patients to long-term treatment compared to standard medical care. The trial found that the device offered no additional benefit, leading to its early termination.
Patients with severe triple-vessel heart disease showed no significant difference in outcomes between CABG and PCI at five years. The FAME-3 trial enrolled 1,500 patients with triple-vessel disease and found that both procedures performed similarly well, considering recent advances in surgical and minimally invasive techniques.
A study found that pulse oximeter readings underestimated blood oxygen levels in patients with dark skin pigment, but also showed a positive bias in 20% of observations. The results suggest that future devices could be designed to indicate uncertainty and improve accuracy across different skin pigmentation categories
A novel AI-powered imaging technique, AngioFFR, has been shown to be comparable to conventional FFR assessment in evaluating patients for PCI. The study found that patients treated with AngioFFR-guided PCI had similar clinical outcomes as those treated with IVUS-guided PCI.
A new transcatheter valve has shown high survival rates and improved quality of life in patients with aortic regurgitation. The trial found an overall mortality rate of 8.1% at one year, meeting non-inferiority to open heart surgery outcomes.
A new mobile integrated health program delivered in-home visits from paramedic teams to people with heart failure did not significantly reduce hospital readmissions or improve health status compared to standard follow-up phone calls. However, the study found that women and younger patients may benefit more from this intervention.
Patients with low surgical risk undergoing transcatheter (TAVR) or surgical aortic valve replacement (SAVR) show comparable death, stroke, and reintervention rates at five years. The study found that TAVR is as effective as surgery in improving symptoms, functional class, and overall quality of life.
A study found that semaglutide significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes. Patients taking semaglutide also experienced improvements in symptoms and quality of life compared to those on a placebo.
An AI model has been developed to detect blocked coronary arteries based on ECG readings, achieving high accuracy and outperforming expert clinicians. The model could help physicians quickly identify patients who require urgent treatment for a heart attack.
A four-year study presented at the American College of Cardiology's Annual Scientific Session found that oral semaglutide reduced cardiovascular death, heart attack, and stroke by 14% compared to a placebo. The drug's benefits are comparable to injectable forms and offer an alternative for patients who prefer not to take injections.
A study presented at the American College of Cardiology's Annual Scientific Session found that dapagliflozin significantly reduced the rate of worsening heart failure in elderly patients with heart failure undergoing transcatheter aortic valve replacement. The trial, called DapaTAVI, enrolled 1,257 patients and showed a 28% lower rate ...
A new study finds that prothrombin concentrate is superior to frozen plasma in controlling bleeding during heart surgery, reducing major bleeding events by nearly 50%. The concentrated product caused fewer adverse effects and saved hospitals resources, suggesting a potential shift in treatment guidelines.
In an open-label study, patients hospitalized for a serious heart attack who received rivaroxaban or warfarin had similar efficacy and safety outcomes. Rivaroxaban showed comparable results in dissolving left ventricular blood clots at three months follow-up.
A Phase 2b trial found lorundrostat significantly reduced blood pressure in patients with uncontrolled hypertension by 7.9 mm Hg and 6.5 mm Hg compared to placebo at 12 weeks. The drug showed an acceptable side effect profile, with consistent patterns across secondary endpoints.
Researchers studied women with ischemia symptoms without blockages in their heart arteries. The five-year trial found no significant difference between intensive medical therapy and usual care for serious cardiovascular events.
A new study found that three months of dual antiplatelet therapy (DAPT) was better than one month for reducing heart attacks, strokes, and other adverse events without increasing bleeding risk in high-risk patients. For low-risk patients, three months of DAPT was comparable to 12 months in reducing adverse events, while being better th...
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A new antidote, bentracimab, safely restored platelet function in patients on ticagrelor, reducing the risk of bleeding during urgent surgery or major bleeding events. The study showed similar results for surgical and bleeding patients, with 94.3% achieving normal blood clotting after treatment.
The American College of Cardiology has recognized 10 young researchers with the Young Author Achievement Award, showcasing their groundbreaking work published in JACC journals. The awardees will be recognized during ACC.25 in Chicago, March 29-31, 2025.
The American College of Cardiology recognizes exceptional peer reviewers contributing to JACC's mission to publish impactful clinical research. The 2025 Simon Dack Award recipients and Elite Reviewers have made significant contributions to advancing cardiovascular care.
The American College of Cardiology and Association of Black Cardiologists have selected three recipients of the Merck Research Fellowship Award. The award provides $100,000 in funding to support one year of cardiovascular research.
The American College of Cardiology will honor three early career cardiologists with the Hani Najm Global Scholar Award Observership Program at ACC.25, taking place in Chicago. The program encourages international cardiology professionals to share knowledge and enhance their training by shadowing a practicing cardiologist in the US.
The American College of Cardiology has recognized 21 distinguished award recipients for their outstanding contributions to the field of cardiovascular medicine. The awardees will be honored during Convocation at ACC.25 in Chicago, showcasing their remarkable work in transforming cardiovascular care and improving heart health.
The American College of Cardiology is recognizing five primary authors with the William W. Parmley Young Author Achievement Award for their exceptional research papers published in JACC. The award highlights remarkable first-author publications by trainees in JACC and aims to elevate trainee-led research in the journal.
The American College of Cardiology is presenting the inaugural JACC Rocket Fuel Consultant Award to five experts who have streamlined the review process and ensured high-quality research submissions. The award aims to fuel JACC's mission to improve heart health through pertinent research.
The American College of Cardiology recognizes Jennifer Mateo Soto and Opeyemi Olalekan Oni for their innovative cardiovascular research projects in low- and middle-income countries. The awardees will receive $25,000 to support their research, which aims to improve the care of people at risk or living with cardiovascular disease.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
People with heart failure who can travel outside their home without assistance are less likely to be hospitalized or die within a year. Life-space mobility, a measure of how far patients move in their communities, is a reliable marker of risk for adverse outcomes in chronic diseases.
A new study finds a positive correlation between microplastic concentration and the prevalence of high blood pressure, diabetes, stroke, but not cancer. Higher microplastic pollution is associated with a higher risk of disease, suggesting a potential link between microplastics and chronic noncommunicable diseases.
The rate of maternal mortality related to cardiovascular causes has more than doubled between 1999 and 2022 in the US. Researchers attribute the increase to factors such as socioeconomic disadvantages, limited access to healthcare, and higher prevalence of risk factors.
A recent study has found that people diagnosed with colorectal cancer are more likely to die from cardiovascular causes, particularly in the first two years after diagnosis. The study analyzed data from over 630,000 US adults and found a 16% increased risk of cardiovascular mortality among those with colorectal cancer.
A deep learning model analyzes breast arterial calcification and translates results into a cardiovascular risk score, helping identify patients at higher risk of heart disease. The tool is particularly useful for younger women, who can benefit from early interventions.
A new study suggests that dividing average daily heart rate by steps taken per day provides a more reliable indicator of cardiovascular fitness. People with elevated DHRPS were twice as likely to have Type 2 diabetes and more than 1.5 times as likely to have high blood pressure compared to those with lower DHRPS.
A study found that women who underwent bilateral oophorectomy were more likely to develop heart failure later in life. The researchers suggest that early menopause may be a contributing factor to this increased risk, and recommend closer cardiovascular monitoring for women contemplating the procedure.
Researchers report a significant increase in congenital heart defects in states with restrictive abortion laws, exceeding pre-Dobbs trends. This trend is associated with higher healthcare utilization needs and potential non-financial strains on families.
Two new studies have found a substantial link between cannabis use and an increased risk of heart attack. The studies, one retrospective and one meta-analysis, pooled data from over 4.6 million people, showing that cannabis users under the age of 50 were six times more likely to suffer a heart attack than non-users.
A study found that a healthy plant-based diet was associated with a 17-24% lower risk of death from any cause, cardiovascular disease or cancer. Researchers analyzed data from nearly 78,000 people with cardiometabolic disorders and found that closer adherence to a healthful plant-based diet brought significant benefits.
Researchers found that lifestyle and health factors linked with heart disease have a stronger impact on women than men. Women were more likely to have fewer negative risk factors but faced a greater increase in cardiovascular events if they had more negative risk factors compared to men.
The American College of Cardiology has issued a new clinical policy providing streamlined processes for the evaluation and management of cardiogenic shock. The guidelines emphasize early recognition, comprehensive assessment, and effective medical management to preserve organ performance and reduce mortality rates.